The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
In the latest session, Fresenius Medical Care AG ADR (NYSE: FMS) closed at $23.37 down -0.85% from its previous closing price of $23.57. In other words, the price has decreased by -$0.85 from its previous closing price. On the day, 0.95 million shares were traded. FMS stock price reached its highest trading level at $23.65 during the session, while it also had its lowest trading level at $23.25.
Ratios:
For a deeper understanding of Fresenius Medical Care AG ADR’s stock, let’s take a closer look at its various ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 9.18 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 6.82. For the most recent quarter (mrq), Quick Ratio is recorded 1.00 and its Current Ratio is at 1.36. In the meantime, Its Debt-to-Equity ratio is 0.81 whereas as Long-Term Debt/Eq ratio is at 0.72.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, FMS now has a Market Capitalization of 13547539456 and an Enterprise Value of 16958830592. As of this moment, Fresenius’s Price-to-Earnings (P/E) ratio for their current fiscal year is 16.96, and their Forward P/E ratio for the next fiscal year is 9.63. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.87. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.62 while its Price-to-Book (P/B) ratio in mrq is 0.89. Its current Enterprise Value per Revenue stands at 0.863 whereas that against EBITDA is 6.915.
Stock Price History:
The Beta on a monthly basis for FMS is 0.89, which has changed by -0.020365775 over the last 52 weeks, in comparison to a change of 0.12469888 over the same period for the S&P500. Over the past 52 weeks, FMS has reached a high of $30.46, while it has fallen to a 52-week low of $22.05. The 50-Day Moving Average of the stock is -7.99%, while the 200-Day Moving Average is calculated to be -9.20%.
Shares Statistics:
For the past three months, FMS has traded an average of 407.17K shares per day and 432320 over the past ten days. A total of 579.70M shares are outstanding, with a floating share count of 579.27M. Insiders hold about 0.07% of the company’s shares, while institutions hold 6.23% stake in the company. Shares short for FMS as of 1763078400 were 766762 with a Short Ratio of 1.88, compared to 1760486400 on 643774.
Dividends & Splits
According to the company, the forward annual dividend rate for FMS is 0.81, from 1.44 in the trailing year. Against a Trailing Annual Dividend Yield of 0.061094616. The stock’s 5-year Average Dividend Yield is 1.3. The current Payout Ratio is 57.49% for FMS, which recently paid a dividend on 2025-05-23 with an ex-dividend date of 2025-05-23. Stock splits for the company last occurred on 2012-12-04 when the company split stock in a 2:1 ratio.
Earnings Estimates
Currently, 2.0 analysts are dedicated to thoroughly evaluating and rating the performance of Fresenius Medical Care AG ADR (FMS) in the stock market.The consensus estimate for the next quarter is $0.49, with high estimates of $0.49 and low estimates of $0.49.
Analysts are recommending an EPS of between $3.92 and $1.73 for the fiscal current year, implying an average EPS of $2.58. EPS for the following year is $2.94, with 6.0 analysts recommending between $4.63 and $2.01.
Revenue Estimates
A total of 5 analysts believe the company’s revenue will be $4.74B this quarter.It ranges from a high estimate of $5.15B to a low estimate of $3.92B. As of. The current estimate, Fresenius Medical Care AG ADR’s year-ago sales were $5.08BFor the next quarter, 5 analysts are estimating revenue of $4.94B. There is a high estimate of $4.94B for the next quarter, whereas the lowest estimate is $4.94B.
A total of 16 analysts have provided revenue estimates for FMS’s current fiscal year. The highest revenue estimate was $19.83B, while the lowest revenue estimate was $19.04B, resulting in an average revenue estimate of $19.56B. In the same quarter a year ago, actual revenue was $19.34BBased on 17 analysts’ estimates, the company’s revenue will be $20.15B in the next fiscal year. The high estimate is $20.78B and the low estimate is $19.64B.
